Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person cilnidipine [extracellular region]

Class:Id	ChemicalDrug:9614120
_displayName	cilnidipine [extracellular region]
_timestamp	2018-12-12 00:29:44
compartment	[Compartment:984] extracellular region
created	[InstanceEdit:9614134] Jassal, Bijay, 2018-07-24
crossReference	[DatabaseIdentifier:9628016] ChEBI:31399
disease	[Disease:9608426] hypertension
literatureReference	[LiteratureReference:9614038] Cilnidipine is a novel slow-acting blocker of vascular L-type calcium channels that does not target protein kinase C [LiteratureReference:9614054] Effects of cilnidipine, a novel dihydropyridine calcium antagonist, on autonomic function, ambulatory blood pressure and heart rate in patients with essential hypertension
modified	[InstanceEdit:9616750] Weiser, JD [InstanceEdit:9616752] Shorser, Solomon, 2018-08-13 [InstanceEdit:9619953] Wu, G, 2018-09-19 [InstanceEdit:9625644] Jassal, Bijay, 2018-10-22 [InstanceEdit:9627975] Wu, G, 2018-11-05 [InstanceEdit:9631716] Wu, G, 2018-12-12
name	cilnidipine
referenceEntity	[ReferenceTherapeutic:9614107] cilnidipine [Guide to Pharmacology:7767]
stableIdentifier	[StableIdentifier:9614145] R-ALL-9614120.1
(hasMember)	[DefinedSet:9614108] Class IV antihypertensives [extracellular region]
[Change default viewing format]

No pathways have been reviewed or authored by cilnidipine [extracellular region] (9614120)